Pyrophosphate antiviral
Foscarnet sodium
Brand names: Foscavir
Adult dose
Dose: CMV induction: 60mg/kg every 8h or 90mg/kg every 12h IV for 14–21 days. Maintenance 60–120mg/kg/day
Route: IV
Frequency: q8-12h
Dose adjustments
Renal
Mandatory dose reduction per CrCl — refer to BNF
Clinical pearls
- CMV retinitis in immunocompromised, aciclovir-resistant HSV/VZV
- Pre-/post-hydration mandatory
Contraindications
- Severe renal impairment without dose adjustment
Side effects
- Severe nephrotoxicity (dose-limiting)
- Hypocalcaemia/hypomagnesaemia
- Genital ulceration
- Anaemia
- Seizures
- Phlebitis
Interactions
- Other nephrotoxins (aminoglycosides, ciclosporin, amphotericin)
- IV pentamidine (severe hypocalcaemia)
Monitoring
- U&E daily
- Ca/Mg/PO4
- FBC
Reference: BNF; SmPC; BHIVA; https://bnf.nice.org.uk/drugs/foscarnet-sodium/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023